Skip to main content
Erschienen in: Current HIV/AIDS Reports 2/2013

01.06.2013 | The Global Epidemic (Q Abdool Karim, Section Editor)

Antiretroviral Drug Regimens to Prevent Mother-To-Child Transmission of HIV: A Review of Scientific, Program, and Policy Advances for Sub-Saharan Africa

verfasst von: Benjamin H. Chi, Jeffrey S. A. Stringer, Dhayendre Moodley

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Considerable advances have been made in the effort to prevent mother-to-child HIV transmission (PMTCT) in sub-Saharan Africa. Clinical trials have demonstrated the efficacy of antiretroviral regimens to interrupt HIV transmission through the antenatal, intrapartum, and postnatal periods. Scientific discoveries have been rapidly translated into health policy, bolstered by substantial investment in health infrastructure capable of delivering increasingly complex services. A new scientific agenda is also emerging, one that is focused on the challenges of effective and sustainable program implementation. Finally, global campaigns to “virtually eliminate” pediatric HIV and dramatically reduce HIV-related maternal mortality have mobilized new resources and renewed political will. Each of these developments marks a major step in regional PMTCT efforts; their convergence signals a time of rapid progress in the field, characterized by an increased interdependency between clinical research, program implementation, and policy. In this review, we take stock of recent advances across each of these areas, highlighting the challenges—and opportunities—of improving health services for HIV-infected mothers and their children across the region.
Literatur
1.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. Geneva: World Health Organization; 2012. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. Geneva: World Health Organization; 2012.
3.
Zurück zum Zitat Centers for Disease Control and Prevention. Achievements in public health. Reduction in perinatal transmission of HIV infection–United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55:592–7. Centers for Disease Control and Prevention. Achievements in public health. Reduction in perinatal transmission of HIV infection–United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55:592–7.
4.
Zurück zum Zitat Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008;22:973–81.PubMedCrossRef Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008;22:973–81.PubMedCrossRef
5.
Zurück zum Zitat Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;354:795–802.PubMed Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;354:795–802.PubMed
6.
Zurück zum Zitat Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S78–87.PubMedCrossRef Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S78–87.PubMedCrossRef
7.
Zurück zum Zitat Stover J, Korenromp EL, Blakley M, Komatsu R, Viisainen K, Bollinger L, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One. 2011;6:e21048.PubMedCrossRef Stover J, Korenromp EL, Blakley M, Komatsu R, Viisainen K, Bollinger L, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One. 2011;6:e21048.PubMedCrossRef
8.
Zurück zum Zitat • World Health Organization. Antiretroviral therapy for treating pregnant women and preventing HIV infection in infants; recommendations for a public health approach - 2010 revision. Geneva, Switzerland: WHO Press; 2010. These World Health Organization recommendations were the first to endorse highly efficacious antiretroviral interventions for the prevention of mother-to-child HIV transmission in resource-constrained settings, including extension of regimens through the breastfeeding period. This document introduced the 2 strategies (ie, Option A, Option B) that now frame the scientific and policy discussions in the field. • World Health Organization. Antiretroviral therapy for treating pregnant women and preventing HIV infection in infants; recommendations for a public health approach - 2010 revision. Geneva, Switzerland: WHO Press; 2010. These World Health Organization recommendations were the first to endorse highly efficacious antiretroviral interventions for the prevention of mother-to-child HIV transmission in resource-constrained settings, including extension of regimens through the breastfeeding period. This document introduced the 2 strategies (ie, Option A, Option B) that now frame the scientific and policy discussions in the field.
10.
Zurück zum Zitat Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–80.PubMedCrossRef Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–80.PubMedCrossRef
11.
Zurück zum Zitat Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982–91.PubMedCrossRef Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982–91.PubMedCrossRef
12.
Zurück zum Zitat Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353:773–80.PubMedCrossRef Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353:773–80.PubMedCrossRef
13.
Zurück zum Zitat •• Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271–81. Direct comparison of postpartum maternal and infant antiretroviral prophylaxis during breastfeeding in a randomized clinical trial setting.PubMedCrossRef •• Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271–81. Direct comparison of postpartum maternal and infant antiretroviral prophylaxis during breastfeeding in a randomized clinical trial setting.PubMedCrossRef
14.
Zurück zum Zitat • Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding — the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8:e1001015. Single-arm study demonstrating safety, effectiveness, and feasibility of maternal combination antiretroviral prophylaxis during breastfeeding.PubMedCrossRef • Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding — the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8:e1001015. Single-arm study demonstrating safety, effectiveness, and feasibility of maternal combination antiretroviral prophylaxis during breastfeeding.PubMedCrossRef
15.
Zurück zum Zitat •• Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomized controlled trial. Lancet Infect Dis. 2011;11:171–80. Randomized controlled trial comparing maternal combination antiretroviral prophylaxis from pregnancy through breastfeeding to short-course zidovudine and peripartum neviraipine regimens, as recommended in the 2006 WHO guidelines.CrossRef •• Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomized controlled trial. Lancet Infect Dis. 2011;11:171–80. Randomized controlled trial comparing maternal combination antiretroviral prophylaxis from pregnancy through breastfeeding to short-course zidovudine and peripartum neviraipine regimens, as recommended in the 2006 WHO guidelines.CrossRef
16.
Zurück zum Zitat •• Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362:2282–94. Comparison of 3 maternal antiretroviral regimens to prevent mother-to-child transmission of HIV during pregnancy and breastfeeding. This trial reported one of the lowest transmission rates among HIV-exposed breastfeeding infants.PubMedCrossRef •• Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362:2282–94. Comparison of 3 maternal antiretroviral regimens to prevent mother-to-child transmission of HIV during pregnancy and breastfeeding. This trial reported one of the lowest transmission rates among HIV-exposed breastfeeding infants.PubMedCrossRef
17.
Zurück zum Zitat Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–28.PubMedCrossRef Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–28.PubMedCrossRef
18.
Zurück zum Zitat McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, Hall DB, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6:e1000172.PubMedCrossRef McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, Hall DB, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6:e1000172.PubMedCrossRef
19.
Zurück zum Zitat Six week extended-dose nevirapine (SWEN) study team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300–13. Six week extended-dose nevirapine (SWEN) study team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300–13.
20.
Zurück zum Zitat Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119–29.PubMedCrossRef Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119–29.PubMedCrossRef
21.
Zurück zum Zitat •• Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomized, double-blind, placebo-controlled trial. Lancet. 2012;379:221–8. A large multi-center randomized controlled trial of extended infant nevirapine for 6 months to reduce HIV transmission during breastfeeding.PubMedCrossRef •• Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomized, double-blind, placebo-controlled trial. Lancet. 2012;379:221–8. A large multi-center randomized controlled trial of extended infant nevirapine for 6 months to reduce HIV transmission during breastfeeding.PubMedCrossRef
22.
Zurück zum Zitat Hudgens MG, Taha TE, Omer SB, Jamieson DJ, Lee H, Mofenson LM, et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis. 2013;56:131–9.PubMedCrossRef Hudgens MG, Taha TE, Omer SB, Jamieson DJ, Lee H, Mofenson LM, et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis. 2013;56:131–9.PubMedCrossRef
23.
Zurück zum Zitat Omer SB. Twelve-month follow-up of 6 week extended dose nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS. 2011;25:767–76.PubMedCrossRef Omer SB. Twelve-month follow-up of 6 week extended dose nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS. 2011;25:767–76.PubMedCrossRef
24.
Zurück zum Zitat Taha TE, Li Q, Hoover DR, Mipando L, Nkanaunena K, Thigpen MC, et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr. 2011;57:319–25.PubMedCrossRef Taha TE, Li Q, Hoover DR, Mipando L, Nkanaunena K, Thigpen MC, et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr. 2011;57:319–25.PubMedCrossRef
25.
Zurück zum Zitat Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomized controlled trial. Lancet. 2012;379:2449–58. doi:10.1016/S0140-6736(12)60321-3.PubMedCrossRef Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomized controlled trial. Lancet. 2012;379:2449–58. doi:10.​1016/​S0140-6736(12)60321-3.PubMedCrossRef
26.
Zurück zum Zitat Kesho Bora Study Group. Maternal HIV-1 disease progression 18–24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. Clin Infect Dis. 2012;55:449–60.CrossRef Kesho Bora Study Group. Maternal HIV-1 disease progression 18–24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. Clin Infect Dis. 2012;55:449–60.CrossRef
27.
Zurück zum Zitat Hargrove JW, Humphrey JH, Group ZS. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010;24:F11–4.PubMedCrossRef Hargrove JW, Humphrey JH, Group ZS. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010;24:F11–4.PubMedCrossRef
28.
Zurück zum Zitat Grinsztejn B, Ribaudo H, Cohen MS, Swindells S, Badel-Faesen S, Burns D, et al, editors. Effects of early vs delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial [Abstract MOAX0105]. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; Rome, Italy.2011. Grinsztejn B, Ribaudo H, Cohen MS, Swindells S, Badel-Faesen S, Burns D, et al, editors. Effects of early vs delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial [Abstract MOAX0105]. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; Rome, Italy.2011.
29.
Zurück zum Zitat Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25:1611–8.PubMedCrossRef Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25:1611–8.PubMedCrossRef
30.
Zurück zum Zitat Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695–705.PubMedCrossRef Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695–705.PubMedCrossRef
31.
Zurück zum Zitat Shapiro RL, Souda S, Parekh N, Binda K, Kayembe M, Lockman S, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLoS One. 2012;7:e31580.PubMedCrossRef Shapiro RL, Souda S, Parekh N, Binda K, Kayembe M, Lockman S, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLoS One. 2012;7:e31580.PubMedCrossRef
32.
Zurück zum Zitat Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1461–70.PubMedCrossRef Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1461–70.PubMedCrossRef
33.
Zurück zum Zitat Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301–4.PubMedCrossRef Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301–4.PubMedCrossRef
34.
Zurück zum Zitat Siberry GK, Williams PL, Mendez H, Seage 3rd GR, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151–9.PubMedCrossRef Siberry GK, Williams PL, Mendez H, Seage 3rd GR, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151–9.PubMedCrossRef
35.
Zurück zum Zitat Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.PubMedCrossRef Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.PubMedCrossRef
36.
Zurück zum Zitat Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. 2011;56:428–36.PubMedCrossRef Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. 2011;56:428–36.PubMedCrossRef
37.
Zurück zum Zitat Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr. 2011;56:131–8.PubMedCrossRef Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr. 2011;56:131–8.PubMedCrossRef
38.
Zurück zum Zitat Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One. 2009;4:e4096.PubMedCrossRef Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One. 2009;4:e4096.PubMedCrossRef
39.
Zurück zum Zitat Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, et al. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011;25:911–7.PubMedCrossRef Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, et al. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011;25:911–7.PubMedCrossRef
40.
Zurück zum Zitat Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2012. Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2012.
41.
Zurück zum Zitat Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, et al. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retrovir. 2011;27:823–9.PubMedCrossRef Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, et al. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retrovir. 2011;27:823–9.PubMedCrossRef
42.
Zurück zum Zitat Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.PubMedCrossRef Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.PubMedCrossRef
43.
Zurück zum Zitat Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52:1069–76.PubMedCrossRef Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52:1069–76.PubMedCrossRef
44.
Zurück zum Zitat Mahy M, Stover J, Kiragu K, Hayashi C, Akwara P, Luo C, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect. 2010;86 Suppl 2:ii48–55.PubMedCrossRef Mahy M, Stover J, Kiragu K, Hayashi C, Akwara P, Luo C, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect. 2010;86 Suppl 2:ii48–55.PubMedCrossRef
45.
Zurück zum Zitat Ciaranello AL, Perez F, Keatinge J, Park JE, Engelsmann B, Maruva M, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012;9:e1001156.PubMedCrossRef Ciaranello AL, Perez F, Keatinge J, Park JE, Engelsmann B, Maruva M, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012;9:e1001156.PubMedCrossRef
46.
Zurück zum Zitat Stringer EM, Chi BH, Chintu N, Creek TL, Ekouevi DK, Coetzee D, et al. Monitoring effectiveness of programs to prevent mother-to-child HIV transmission in lower-income countries. Bull World Health Organ. 2008;86:57–62.PubMedCrossRef Stringer EM, Chi BH, Chintu N, Creek TL, Ekouevi DK, Coetzee D, et al. Monitoring effectiveness of programs to prevent mother-to-child HIV transmission in lower-income countries. Bull World Health Organ. 2008;86:57–62.PubMedCrossRef
47.
Zurück zum Zitat Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59.PubMedCrossRef Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59.PubMedCrossRef
48.
Zurück zum Zitat Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011;56:e45–8.PubMedCrossRef Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011;56:e45–8.PubMedCrossRef
49.
Zurück zum Zitat Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS. 2012;26:2361–73.PubMedCrossRef Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS. 2012;26:2361–73.PubMedCrossRef
50.
Zurück zum Zitat Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health. 2010;15:825–32.PubMedCrossRef Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health. 2010;15:825–32.PubMedCrossRef
51.
Zurück zum Zitat Hussain A, Moodley D, Naidoo S, Esterhuizen TM. Pregnant women's access to PMTCT and ART services in South Africa and implications for universal antiretroviral treatment. PLoS One. 2011;6:e27907.PubMedCrossRef Hussain A, Moodley D, Naidoo S, Esterhuizen TM. Pregnant women's access to PMTCT and ART services in South Africa and implications for universal antiretroviral treatment. PLoS One. 2011;6:e27907.PubMedCrossRef
52.
Zurück zum Zitat Myer L, Zulliger R, Black S, Pienaar D, Bekker LG. Pilot program for the rapid initiation of antiretroviral therapy in pregnancy in Cape Town, South Africa. AIDS Care. 2012;24:986–92.PubMedCrossRef Myer L, Zulliger R, Black S, Pienaar D, Bekker LG. Pilot program for the rapid initiation of antiretroviral therapy in pregnancy in Cape Town, South Africa. AIDS Care. 2012;24:986–92.PubMedCrossRef
53.
Zurück zum Zitat Killam WP, Tambatamba BC, Chintu N, Rouse D, Stringer E, Bweupe M, et al. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS. 2010;24:85–91.PubMedCrossRef Killam WP, Tambatamba BC, Chintu N, Rouse D, Stringer E, Bweupe M, et al. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS. 2010;24:85–91.PubMedCrossRef
54.
Zurück zum Zitat Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet. 2011;378:282–4.PubMedCrossRef Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet. 2011;378:282–4.PubMedCrossRef
55.
Zurück zum Zitat Molisho M, Michaelis A, Shelley K, Reiner C, Romano S, Kisimbi T, et al. Increasing retention in care for prevention of MTCT in Machinga District, Malawi through an integrated service delivery model: the Mother-Infant Pair (MIP) clinic [Abstract TUPE763]. 19th International AIDS Conference. 2012. Molisho M, Michaelis A, Shelley K, Reiner C, Romano S, Kisimbi T, et al. Increasing retention in care for prevention of MTCT in Machinga District, Malawi through an integrated service delivery model: the Mother-Infant Pair (MIP) clinic [Abstract TUPE763]. 19th International AIDS Conference. 2012.
56.
Zurück zum Zitat Besser M, Sogaula N, Goheen M, Myers A, Nolan M. Improving uptake of early infant HIV diagnosis through simple interventions: lessons learned at mother2mother's innovation center, South Africa [Abstract THPE0286]. 18th International AIDS Conference. 2010. Besser M, Sogaula N, Goheen M, Myers A, Nolan M. Improving uptake of early infant HIV diagnosis through simple interventions: lessons learned at mother2mother's innovation center, South Africa [Abstract THPE0286]. 18th International AIDS Conference. 2010.
57.
Zurück zum Zitat Technau K-G, De Tolly K, Sherman G, Kuhn L, Benjamin P, Bassett J, et al. Mobile text messaging improves PMTCT follow-up in South African public setting [Abstract TUPE292]. 6th IAS Conference on HIV Pathogenesis and Treatment. 2011. Technau K-G, De Tolly K, Sherman G, Kuhn L, Benjamin P, Bassett J, et al. Mobile text messaging improves PMTCT follow-up in South African public setting [Abstract TUPE292]. 6th IAS Conference on HIV Pathogenesis and Treatment. 2011.
58.
Zurück zum Zitat Seidenberg P, Nicholson S, Schaefer M, Semrau K, Bweupe M, Masese N, et al. Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test results. Bull World Health Organ. 2012;90:348–56.PubMedCrossRef Seidenberg P, Nicholson S, Schaefer M, Semrau K, Bweupe M, Masese N, et al. Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test results. Bull World Health Organ. 2012;90:348–56.PubMedCrossRef
59.
Zurück zum Zitat Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26:2039–52.PubMedCrossRef Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26:2039–52.PubMedCrossRef
60.
Zurück zum Zitat Myer L, Cornell M, Fox M, Garone D, Wood R, Prozesky H, et al, editors. Loss to follow-up and mortality among pregnant and non-pregnant women initiating ART: South Africa [Abstract 22]. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. 2012. Myer L, Cornell M, Fox M, Garone D, Wood R, Prozesky H, et al, editors. Loss to follow-up and mortality among pregnant and non-pregnant women initiating ART: South Africa [Abstract 22]. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. 2012.
61.
Zurück zum Zitat Ghanotakis E, Miller L, Spensley A. Country adaptation of the 2010 World Health Organization recommendations for the prevention of mother-to-child transmission of HIV. Bull World Health Organ. 2012;90:921–31.PubMed Ghanotakis E, Miller L, Spensley A. Country adaptation of the 2010 World Health Organization recommendations for the prevention of mother-to-child transmission of HIV. Bull World Health Organ. 2012;90:921–31.PubMed
63.
Zurück zum Zitat • Business Leadership Council, UNICEF. A business case for Options B and B+. July 2012. http://www.unicef.org/aids/files/hiv_BusinesscaseB.pdf. Accessed on January 8, 2013. This case study provides programmatic and operational justifications for UNICEF’s endorsement of Option B/B+ over Option A for the prevention of mother-to-child transmission of HIV. • Business Leadership Council, UNICEF. A business case for Options B and B+. July 2012. http://​www.​unicef.​org/​aids/​files/​hiv_​BusinesscaseB.​pdf. Accessed on January 8, 2013. This case study provides programmatic and operational justifications for UNICEF’s endorsement of Option B/B+ over Option A for the prevention of mother-to-child transmission of HIV.
64.
Zurück zum Zitat • World Health Organization. Use of antiretroviral drugs for treating pregnant women and prevention HIV infection in infants: Executive summary, April 2012. http://www.who.int/hiv/PMTCT_update.pdf. Accessed on December 26, 2012. This programmatic update indicated the World Health Organization’s preference for Options B/B+ for the prevention of mother-to-child transmission of HIV. • World Health Organization. Use of antiretroviral drugs for treating pregnant women and prevention HIV infection in infants: Executive summary, April 2012. http://​www.​who.​int/​hiv/​PMTCT_​update.​pdf. Accessed on December 26, 2012. This programmatic update indicated the World Health Organization’s preference for Options B/B+ for the prevention of mother-to-child transmission of HIV.
66.
Zurück zum Zitat Kagaayi J, Gray RH, Ddungu V, Nabwire M, Ssebagala D, Ndyanabo A, et al. Early impact of extended prophylaxis with nevirapine on HIV acquisition among infants in rural Rakai, Uganda [Abstract MOPE0279]. 18th International AIDS Conference. 2010. Kagaayi J, Gray RH, Ddungu V, Nabwire M, Ssebagala D, Ndyanabo A, et al. Early impact of extended prophylaxis with nevirapine on HIV acquisition among infants in rural Rakai, Uganda [Abstract MOPE0279]. 18th International AIDS Conference. 2010.
67.
Zurück zum Zitat Feinstein L, Edmonds A, Lusiama J, Matumona Y, Thompson D, Chalachala JL, et al. Extended prophylaxis with nevriapine for HIV-exposed infants: early outcomes in field conditions [Abstract WEPE213]. 19th International AIDS Conference. 2012. Feinstein L, Edmonds A, Lusiama J, Matumona Y, Thompson D, Chalachala JL, et al. Extended prophylaxis with nevriapine for HIV-exposed infants: early outcomes in field conditions [Abstract WEPE213]. 19th International AIDS Conference. 2012.
68.
Zurück zum Zitat Diouf K, Manjiru M, Tuma N, Dillabaugh L, Ndege V, Oyaro P, et al. Implementation of daily nevirapine prophylaxis in HIV-exposed breastfeeding infants in western Kenya [Abstract LBPE52]. 19th International AIDS Conference. 2012. Diouf K, Manjiru M, Tuma N, Dillabaugh L, Ndege V, Oyaro P, et al. Implementation of daily nevirapine prophylaxis in HIV-exposed breastfeeding infants in western Kenya [Abstract LBPE52]. 19th International AIDS Conference. 2012.
69.
Zurück zum Zitat Walakira M, Sripipatana T, Mirembe Kunya B, Kajungu E, Namubiru M, Musinguzi H, et al. The challenge of translating policy into practice: the impact of revised prevention of mother-to-child transmission of HIV guideline implementation on uptake of infant antiretroviral prophylaxis in southwestern Uganda [Abstract MOPE609]. 19th International AIDS Conference. 2012. Walakira M, Sripipatana T, Mirembe Kunya B, Kajungu E, Namubiru M, Musinguzi H, et al. The challenge of translating policy into practice: the impact of revised prevention of mother-to-child transmission of HIV guideline implementation on uptake of infant antiretroviral prophylaxis in southwestern Uganda [Abstract MOPE609]. 19th International AIDS Conference. 2012.
70.
Zurück zum Zitat Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Ghidinelli MN, Syakantu G. Field effectiveness of WHO PMTCT guidelines in preventing postnatal HIV transmission in resource-limited settings: operational barriers and complexities related to the implementation of extended infant prophylaxis [Abstract TUPE177]. 19th International AIDS. Conference 2012. Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Ghidinelli MN, Syakantu G. Field effectiveness of WHO PMTCT guidelines in preventing postnatal HIV transmission in resource-limited settings: operational barriers and complexities related to the implementation of extended infant prophylaxis [Abstract TUPE177]. 19th International AIDS. Conference 2012.
71.
Zurück zum Zitat Changala M, Kapyata H, Kahula M, Siachiwena C, Kalichini P, Muvuma S, et al. Mothers' confusion over the extended nevirapine regimen for HIV-exposed infants in resource-limited settings [Abstract LBPE30]. 19th International AIDS Conference. 2012. Changala M, Kapyata H, Kahula M, Siachiwena C, Kalichini P, Muvuma S, et al. Mothers' confusion over the extended nevirapine regimen for HIV-exposed infants in resource-limited settings [Abstract LBPE30]. 19th International AIDS Conference. 2012.
72.
Zurück zum Zitat Gartland MG, Chintu NT, Li MS, Lembalemba MK, Mulenga SN, Bweupe M, et al. Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia. AIDS. In press. Gartland MG, Chintu NT, Li MS, Lembalemba MK, Mulenga SN, Bweupe M, et al. Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia. AIDS. In press.
73.
Zurück zum Zitat Chanda J, Rukunda Karekezi B, Milligan C, Kassa Lukabya JL, Kagabo H, Ndikubwimana C, et al. Pediatric HIV-free survival at 18 months in IntraHealth-supported prevention of mother-to-child transmission programs in Rwanda [Abstract WEPE192]. 19th International AIDS Conference. 2012. Chanda J, Rukunda Karekezi B, Milligan C, Kassa Lukabya JL, Kagabo H, Ndikubwimana C, et al. Pediatric HIV-free survival at 18 months in IntraHealth-supported prevention of mother-to-child transmission programs in Rwanda [Abstract WEPE192]. 19th International AIDS Conference. 2012.
74.
Zurück zum Zitat Konate J, Nadembega CWM, Traore HA, Meda N, Banse K, Marechai V, et al. Low HIV-1 transmission from mother-to-child among infected pregnant women with a CD4 count above 350 cells per μl and receiving perinatal antiretroviral prophylactic regimens in Ouagadougou, Burkina Faso [Abstract WEPE200]. 19th International AIDS Conference. 2012. Konate J, Nadembega CWM, Traore HA, Meda N, Banse K, Marechai V, et al. Low HIV-1 transmission from mother-to-child among infected pregnant women with a CD4 count above 350 cells per μl and receiving perinatal antiretroviral prophylactic regimens in Ouagadougou, Burkina Faso [Abstract WEPE200]. 19th International AIDS Conference. 2012.
75.
Zurück zum Zitat Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, Keapoletswe K, Tlale J, et al. Highly active antiretroviral therapy vs zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana. J Acquir Immune Defic Syndr. 2011;58:353–7.PubMedCrossRef Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, Keapoletswe K, Tlale J, et al. Highly active antiretroviral therapy vs zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana. J Acquir Immune Defic Syndr. 2011;58:353–7.PubMedCrossRef
76.
Zurück zum Zitat Zolfo M, De Weggheleire A, Schouten E, Lynen L. Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr. 2010;55:287–9.PubMedCrossRef Zolfo M, De Weggheleire A, Schouten E, Lynen L. Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr. 2010;55:287–9.PubMedCrossRef
77.
Zurück zum Zitat Wagner BG, Blower S. Universal access to HIV treatment vs universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One. 2012;7:e41212.PubMedCrossRef Wagner BG, Blower S. Universal access to HIV treatment vs universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One. 2012;7:e41212.PubMedCrossRef
78.
Zurück zum Zitat Auld AF, Bolu O, Creek T, Lindegren ML, Rivadeneira E, Dale H, et al. Potential impact and cost-effectiveness of the 2009 "rapid advice" PMTCT guidelines - 15 resource-limited countries, 2010 [Abstract WEAE0205]. 18th International AIDS Conference. 2010. Auld AF, Bolu O, Creek T, Lindegren ML, Rivadeneira E, Dale H, et al. Potential impact and cost-effectiveness of the 2009 "rapid advice" PMTCT guidelines - 15 resource-limited countries, 2010 [Abstract WEAE0205]. 18th International AIDS Conference. 2010.
79.
Zurück zum Zitat Revill P, Sculpher M, Walker S, Shasela CS, Kayira D, Hosseinipour MC, et al. The cost-effectiveness of maternal and infant antiretroviral regimens to prevent vertical HIV transmission in Malawi [Abstract FRAE0102]. 19th International AIDS Conference. 2012. Revill P, Sculpher M, Walker S, Shasela CS, Kayira D, Hosseinipour MC, et al. The cost-effectiveness of maternal and infant antiretroviral regimens to prevent vertical HIV transmission in Malawi [Abstract FRAE0102]. 19th International AIDS Conference. 2012.
80.
Zurück zum Zitat McCarthy E, Ipuge Y, Ramadhani A, Njau PF, Michaelis A, Essajee S. Cost-effectiveness of Options A and B of the 2010 WHO PMTCT antiretroviral guidelines in Tanzania [Abstract TUPE419]. 19th International AIDS Conference. 2012. McCarthy E, Ipuge Y, Ramadhani A, Njau PF, Michaelis A, Essajee S. Cost-effectiveness of Options A and B of the 2010 WHO PMTCT antiretroviral guidelines in Tanzania [Abstract TUPE419]. 19th International AIDS Conference. 2012.
81.
Zurück zum Zitat • Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, et al. Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clin Infect Dis. 2013;56:430–46. This analysis of Zimbabwe’s national program provides important costing and cost-effectiveness data in support of Options B and B+. • Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, et al. Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clin Infect Dis. 2013;56:430–46. This analysis of Zimbabwe’s national program provides important costing and cost-effectiveness data in support of Options B and B+.
82.
Zurück zum Zitat Dongmo Nquimfack B, Shaffer N, Perriens JH. Drug costs and the prevention of mother-to-child transmission (PMTCT): triple antiretroviral regimens are becoming more attractive [Abstract WEPE185]. 19th International AIDS Conference. 2012. Dongmo Nquimfack B, Shaffer N, Perriens JH. Drug costs and the prevention of mother-to-child transmission (PMTCT): triple antiretroviral regimens are becoming more attractive [Abstract WEPE185]. 19th International AIDS Conference. 2012.
83.
Zurück zum Zitat Mandala J, Torpey K, Kasonde P, Kabaso M, Dirks R, Suzuki C, et al. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Publ Health. 2009;9:314.CrossRef Mandala J, Torpey K, Kasonde P, Kabaso M, Dirks R, Suzuki C, et al. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Publ Health. 2009;9:314.CrossRef
84.
Zurück zum Zitat Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647–56. doi:10.1086/518284.PubMedCrossRef Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647–56. doi:10.​1086/​518284.PubMedCrossRef
85.
Zurück zum Zitat Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539–45.PubMedCrossRef Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539–45.PubMedCrossRef
86.
Zurück zum Zitat Weigel R, Hosseinipour MC, Feldacker C, Gareta D, Tweya H, Chiwoko J, et al. Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi. Trop Med Int Health. 2012;17:751–9.PubMedCrossRef Weigel R, Hosseinipour MC, Feldacker C, Gareta D, Tweya H, Chiwoko J, et al. Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi. Trop Med Int Health. 2012;17:751–9.PubMedCrossRef
87.
Zurück zum Zitat Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011;58:224–8.PubMedCrossRef Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011;58:224–8.PubMedCrossRef
88.
Zurück zum Zitat Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis. 2008;21:25–30.PubMedCrossRef Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis. 2008;21:25–30.PubMedCrossRef
89.
Zurück zum Zitat •• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. The HPTN 052 study provided the first clinical trial data for antiretroviral therapy to prevent HIV transmission from HIV-positive participants to their serodiscordant HIV-negative partners.PubMedCrossRef •• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. The HPTN 052 study provided the first clinical trial data for antiretroviral therapy to prevent HIV transmission from HIV-positive participants to their serodiscordant HIV-negative partners.PubMedCrossRef
91.
Zurück zum Zitat Chirwa Z, Chimbwandira F, Jahn A, Batenganya M. Integrating ART/PMTCT services into MNCH services to enhance test and treat strategy for pregnant women (Option B+): the Malawi experience [Abstract WEPE183]. 19th International AIDS Conference. 2012. Chirwa Z, Chimbwandira F, Jahn A, Batenganya M. Integrating ART/PMTCT services into MNCH services to enhance test and treat strategy for pregnant women (Option B+): the Malawi experience [Abstract WEPE183]. 19th International AIDS Conference. 2012.
92.
Zurück zum Zitat Edmonds A, Thompson D, Okitolonda V, Feinstein L, Kawende B, Behets F. PMTCT decentralization dose not assure optimal service delivery: revelantions from successful individual-level tracking of HIV-positive mothers and their infants [Abstract THAE0103]. 19th International AIDS Conference. 2012. Edmonds A, Thompson D, Okitolonda V, Feinstein L, Kawende B, Behets F. PMTCT decentralization dose not assure optimal service delivery: revelantions from successful individual-level tracking of HIV-positive mothers and their infants [Abstract THAE0103]. 19th International AIDS Conference. 2012.
93.
Zurück zum Zitat Kazembe LN. Spatial modelling of initiation and duration of breastfeeding: analysis of breastfeeding behavior in Malawi - I. World Health Popul. 2008;10:14–31.PubMed Kazembe LN. Spatial modelling of initiation and duration of breastfeeding: analysis of breastfeeding behavior in Malawi - I. World Health Popul. 2008;10:14–31.PubMed
94.
Zurück zum Zitat Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.PubMedCrossRef Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.PubMedCrossRef
95.
Zurück zum Zitat Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1:1–15.PubMedCrossRef Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1:1–15.PubMedCrossRef
96.
Zurück zum Zitat Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.PubMedCrossRef Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.PubMedCrossRef
Metadaten
Titel
Antiretroviral Drug Regimens to Prevent Mother-To-Child Transmission of HIV: A Review of Scientific, Program, and Policy Advances for Sub-Saharan Africa
verfasst von
Benjamin H. Chi
Jeffrey S. A. Stringer
Dhayendre Moodley
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current HIV/AIDS Reports / Ausgabe 2/2013
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-013-0154-z

Weitere Artikel der Ausgabe 2/2013

Current HIV/AIDS Reports 2/2013 Zur Ausgabe

The Global Epidemic (Q Abdool Karim, Section Editor)

Combination Prevention: New Hope for Stopping the Epidemic

The Global Epidemic (Q Abdool Karim, Section Editor)

HIV Testing: Current Practice and Future Directions

The Global Epidemic (Q Abdool Karim, Section Editor)

Overview of the Current State of the Epidemic

The Global Epidemic (Q Abdool Karim, Section Editor)

Addressing Injecting Drug Use in Asia and Eastern Europe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.